HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Clinical trials for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to break Cancer's growth signals
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-10203 in about 392 adults with advanced solid tumors (like breast, lung, or colorectal cancer) that have not responded to other treatments. The drug works by blocking a key cancer growth pathway. The main goals are to find the sa…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 26, 2026 11:36 UTC
-
New drug combo aims to control advanced breast cancer
Disease control Recruiting nowThis study tests two different doses of dalpiciclib combined with letrozole as a first treatment for HR-positive, HER2-negative advanced breast cancer. It will enroll 120 women aged 18-75. The goal is to see which dose works better to control the cancer and delay its growth.
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: wanghaibo • Aim: Disease control
Last updated May 22, 2026 14:01 UTC